Yudai Fujiwara
Overview
Explore the profile of Yudai Fujiwara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fujiwara Y, Kuroda H, Abe T, Nagasawa T, Nakaya I, Ito A, et al.
Sci Rep
. 2025 Feb;
15(1):4547.
PMID: 39915518
We aimed to elucidate the value of ultrasound-based biomarkers for predicting the major life-threatening events in metabolic dysfunction-associated steatotic liver disease (MASLD). We established a prospective cohort of 279 patients...
2.
Kuroda H, Abe T, Kamiyama N, Oguri T, Ito A, Nakaya I, et al.
J Gastroenterol
. 2024 Dec;
60(2):260.
PMID: 39673559
No abstract available.
3.
Kuroda H, Abe T, Kamiyama N, Oguri T, Ito A, Nakaya I, et al.
J Gastroenterol
. 2024 Oct;
60(2):187-196.
PMID: 39470783
Background: Subharmonic-aided pressure estimation (SHAPE) is a technique for determining changes in ambient pressure. We aimed to analyze a novel SHAPE integrated into ultrasound diagnostic equipment to predict patients with...
4.
Kakisaka K, Watanabe T, Yoshida Y, Abe H, Yusa K, Sasaki T, et al.
Hepatol Res
. 2024 Oct;
PMID: 39439017
Background: Steatotic liver disease, characterized by a combination of metabolic dysfunction, alcohol use, or specific etiologies, is a leading cause of chronic liver disease. However, the role of metabolic dysfunction...
5.
Fujiwara Y, Kuroda H, Abe T, Kakisaka K, Nakaya I, Ito A, et al.
Drugs Real World Outcomes
. 2024 Oct;
11(4):701-710.
PMID: 39384684
Background And Objective: Durvalumab plus tremelimumab (Durva/Treme) has recently been approved as a first-line or later-line treatment for patients with unresectable hepatocellular carcinoma (u-HCC) in Japan. We assessed the real-world...
6.
Kakisaka K, Sasaki T, Nakaya I, Watanabe T, Abe H, Yusa K, et al.
Hepatol Res
. 2024 Jun;
PMID: 38873920
Aim: Acute pancreatitis is a complication of acute liver failure (ALF). This study aimed to investigate the prevalence of and clinical features associated with acute pancreatitis in patients with ALF....
7.
Kuroda H, Oguri T, Kamiyama N, Toyoda H, Yasuda S, Imajo K, et al.
Radiology
. 2023 Oct;
309(1):e230341.
PMID: 37787670
Background Because of the global increase in the incidence of nonalcoholic fatty liver disease, the development of noninvasive, widely available, and highly accurate methods for assessing hepatic steatosis is necessary....
8.
Hosomi A, Okachi C, Fujiwara Y
Biochem Biophys Res Commun
. 2023 May;
666:101-106.
PMID: 37182284
Soluble proteins sorted through the secretory pathway contain an N-terminal signal peptide that induces their translocation into the endoplasmic reticulum (ER) from the cytosol. However, a few proteins that lack...
9.
Kuroda H, Abe T, Fujiwara Y, Nagasawa T, Takikawa Y
J Med Ultrason (2001)
. 2021 Aug;
48(4):471-480.
PMID: 34415481
The purpose of this study was to evaluate the diagnostic accuracy of the ultrasound-guided attenuation parameter (UGAP) using the LOGEQ E10 for hepatic steatosis in non-alcoholic fatty liver disease (NAFLD)...
10.
Kuroda H, Fujiwara Y, Abe T, Nagasawa T, Oguri T, Noguchi S, et al.
PLoS One
. 2021 Apr;
16(4):e0249493.
PMID: 33826669
Background And Aims: We investigated the usefulness of combining two-dimensional shear wave elastography and the ultrasound-guided attenuation parameter for assessing the risk of progressive non-alcoholic steatohepatitis, defined as non-alcoholic steatohepatitis...